Positron emission tomography quantification of serotonin1A receptor binding in suicide attempters with major depressive disorder

JAMA Psychiatry

Volumn 72, Issue 2, 2015, Pages 169-178

  Sullivan, Gregory M ^a,b,c   Oquendo, Maria A ^a,b   Milak, Matthew ^a,b   Miller, Jeffrey M ^a,b   Burke, Ainsley ^a,b   Ogden, R Todd ^a,b,d   Parsey, Ramin V ^e   Mann, J John ^a,b,f  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c GAL Manufacturing Company   (United States)

^d Stony Brook University School of Medicine ^*  (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; TRACER; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BECK SCALE FOR SUICIDE IDEATION SCORE; BECK SUICIDE INTENT SCALE; BINDING AFFINITY; BRAIN STEM; BROWN GOODWIN LIFETIME HISTORY OF AGGRESSION SCALE; CLUSTER B PERSONALITY DISORDER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GLOBAL ASSESSMENT SCALE; HAMILTON DEPRESSION RATING SCALE; HOPELESSNESS; HUMAN; LETHALITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDBRAIN RAPHE NUCLEUS; OUTCOME ASSESSMENT; PERSONALITY DISORDER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; REASONS FOR LIVING SCALE; RECEPTOR BINDING; SEROTONIN BRAIN LEVEL; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; CLASSIFICATION; METABOLISM; MIDDLE AGED; PROCEDURES; RAPHE NUCLEUS; SEVERITY OF ILLNESS INDEX;

ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PYRIDINES; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84922247658     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.2406     Document Type: Article

References (79)

1. Centers for Disease Control and Prevention. Control NCfIPa. Web-based Injury Statistics Query and Reporting System (WISQARS). http://www. cdc gov/injury/wisqars/leading-causes-death. html. Accessed October 19, 2012.
2. Mann JJ. A current perspective of suicide and attempted suicide. Ann Intern Med. 2002;136(4): 302-311.
3. AsbergM, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry. 1976;33(10):1193-1197.
4. Cooper SJ, Kelly CB, King DJ. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet. 1992;340(8825):940-941.
5. Mann JJ, Arango V, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies. Br J Psychiatry Suppl. 1989;(8):7-14.
6. Mann JJ, Currier D, Stanley B, Oquendo MA, Amsel LV, Ellis SP. Can biological tests assist prediction of suicide in mood disorders? Int J Neuropsychopharmacol. 2006;9(4):465-474.
7. Mann JJ, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry. 1997;41(2):162-171.
8. Nordstrom P, Samuelsson M, AsbergM, et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav. 1994;24(1):1-9.
9. Oquendo MA, Placidi GP, Malone KM, et al. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Arch Gen Psychiatry. 2003;60(1):14-22.
10. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-year follow-up study. Arch Gen Psychiatry. 1989;46(7):609-612.
11. Malone KM, Corbitt EM, Li S, Mann JJ. Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry. 1996; 168(3):324-329.
12. Linnoila M, Virkkunen M. Biologic correlates of suicidal risk and aggressive behavioral traits. J Clin Psychopharmacol. 1992;12(2)(suppl):19S-20S.
13. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. Biol Psychiatry. 2001;50(10):783-791.
14. Stanley B, Molcho A, Stanley M, et al. Association of aggressive behavior with altered serotonergic function in patients who are not suicidal. Am J Psychiatry. 2000;157(4):609-614.
15. LeytonM, Paquette V, Gravel P, et al. [11C]Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. Eur Neuropsychopharmacol. 2006;16 (3):220-223.
16. Siever LJ, Buchsbaum MS, New AS, et al. d,l-Fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology. 1999;20(5):413-423.
17. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM. A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry. 2000;47(6):540-547.
18. FrankleWG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry. 2005;162(5): 915-923.
19. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression: postmortem evidence for decreased serotonin activity. J Neurosci. 1998;18 (18):7394-7401.
20. BoldriniM, Underwood MD, Mann JJ, Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res. 2008;42(6):433-442.
21. Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre-and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995; 688(1-2):121-133.
22. Lowther S, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW. 5-HT1A receptor binding sites in post-mortem brain samples from depressed suicides and controls. J Affect Disord. 1997;42(2-3):199-207.
23. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology. 1997;16(2): 162-173.
24. Miller JM, Hesselgrave N, Ogden RT, et al. Brain serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder. Biol Psychiatry. 2013;74(10):760-767.
25. Parsey RV, Ogden RT,Miller JM, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry. 2010;68(2):170-178.
26. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59(2): 106-113.
27. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P), Version 2. 0. New York: Biometrics Research,NewYork State Psychiatric Institute; 1994.
28. Beck AT,Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
29. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
30. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
31. First MB, Gibbon M, Spitzer RL,Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press Inc; 1997.
32. Oquendo MA, Halberstam B, Mann JJ. Risk factors for suicidal behavior: the utility and limitations of research instruments. In: First MB, ed. Standardized Evaluation in Clinical Practice. Vol 22. Washington, DC: American Psychiatric Publishing; 2003:103-130.
33. Posner K, Oquendo MA, GouldM, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007; 164(7):1035-1043.
34. Beck AT, Beck R, Kovacs M. Classification of suicidal behaviors, I: quantifying intent and medical lethality. Am J Psychiatry. 1975;132(3):285-287.
35. Beck AT, KovacsM,Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343-352.
36. Mieczkowski TA, Sweeney JA, Haas GL, Junker BW, Brown RP, Mann JJ. Factor composition of the Suicide Intent Scale. Suicide Life Threat Behav. 1993;23(1):37-45.
37. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979;1(2):131-139.
38. Parsey RV, Arango V, Olvet DM, Oquendo MA, Van Heertum RL, John Mann J. Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab. 2005;25 (7):785-793.
39. Parsey RV, SlifsteinM, HwangDR, et al. Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab. 2000;20(7):1111-1133.
40. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal. 2001;5(2):143-156.
41. Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17(3):143-155.
42. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999;7(4):254-266.
43. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839-851.
44. Duvernoy HM. The Human Brain: Surface, Three-Dimensional Sectional Anatomy and MRI. Wien, Austria: Springer-Verlag; 1991.
45. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme; 1988.
46. Kates WR, Abrams MT, Kaufmann WE, Breiter SN, Reiss AL. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiatry Res. 1997;75(1):31-48.
47. Killiany RJ, Moss MB, Nicholson T, Jolesz F, Sandor T. An interactive procedure for extracting features of the brain frommagnetic resonance images: the lobes. Hum Brain Mapp. 1997;5(5):355-363.
48. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539.
49. Parsey RV, Hastings RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry. 2006;163(1):48-51.
50. Hirvonen J, Karlsson H, Kajander J, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol. 2008;11(4):465-476.
51. Oquendo MA, Hastings RS, Huang YY, et al. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry. 2007; 64(2):201-208.
52. Parsey RV, Hastings RS, Oquendo MA, et al. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry. 2006;163(1):52-58.
53. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;31(8):1745-1749.
54. Sullivan GM, Oquendo MA, Simpson N, Van Heertum RL, Mann JJ, Parsey RV. Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety. Biol Psychiatry. 2005; 58(12):947-954.
55. Miller JM, Brennan KG, Ogden TR, et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology. 2009;34 (10):2275-2284.
56. Miller JM, Kinnally EL, Ogden RT, Oquendo MA, Mann JJ, Parsey RV. Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. Synapse. 2009;63(7):565-573.
57. Rabiner EA,WilkinsMR, Turkheimer F, et al. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1, 4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002;301(3):1144-1150.
58. Meltzer CC, Price JC, Mathis CA, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29(12):2258-2265.
59. Ogden RT, Tarpey T. Estimation in regression models with externally estimated parameters. Biostatistics. 2006;7(1):115-129.
60. Parsey RV, Oquendo MA, Simpson NR, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res. 2002;954(2):173-182.
61. Kelly JS, Larkman P, Penington NJ, Rainnie DG, McAllister-Williams H, Hodgkiss J. Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability. Adv Exp Med Biol. 1991;287:177-191.
62. McAllister-Williams RH, Kelly JS. The modulation of calcium channel currents recorded from adult rat dorsal raphe neurones by 5-HT1A receptor or direct G-protein activation. Neuropharmacology. 1995;34(11):1491-1506.
63. Hjorth S, Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 1991;48 (18):1779-1786.
64. Jacobsen JP, Siesser WB, Sachs BD, et al. Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice. Mol Psychiatry. 2012;17(7):694-704.
65. Horesh N, Levi Y, Apter A. Medically serious versus non-serious suicide attempts: relationships of lethality and intent to clinical and interpersonal characteristics. J Affect Disord. 2012;136(3):286-293.
66. Kumar CT, Mohan R, Ranjith G, Chandrasekaran R. Characteristics of high intent suicide attempters admitted to a general hospital. J Affect Disord. 2006;91(1):77-81.
67. Zhang J, Xu H. Degree of suicide intent and the lethality of means employed: a study of Chinese attempters. Arch Suicide Res. 2007;11(4):343-350.
68. Mann JJ, McBride PA, Brown RP, et al. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch Gen Psychiatry. 1992;49 (6):442-446.
69. Hamon M, Bourgoin S, Gozlan H, et al. Biochemical evidence for the 5-HT agonist properties of PAT (8-hydroxy-2-(di-n-propylamino) tetralin) in the rat brain. Eur J Pharmacol. 1984; 100(3-4):263-276.
70. Kumar JS,MilakMS, Majo VJ, et al. Comparison of high and low affinity serotonin 1A receptors by PET in vivo in nonhuman primates. J Pharmacol Sci. 2012;120(3):254-257.
71. Brown GK, Beck AT, Steer RA, Grisham JR. Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol. 2000;68(3):371-377.
72. Fossati A, Barratt ES, Borroni S, Villa D, Grazioli F, Maffei C. Impulsivity, aggressiveness, and DSM-IV personality disorders. Psychiatry Res. 2007;149(1-3):157-167.
73. Lemonde S, Turecki G, Bakish D, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003;23(25): 8788-8799.
74. Vazquez DM, Lopez JF, Van Hoers H,Watson SJ, Levine S. Maternal deprivation regulates serotonin 1A and 2A receptors in the infant rat. Brain Res. 2000;855(1):76-82.
75. Spinelli S, Chefer S, Carson RE, et al. Effects of early-life stress on serotonin1A receptors in juvenile Rhesus monkeys measured by positron emission tomography. Biol Psychiatry. 2010;67(12):1146-1153.
76. Bach-Mizrachi H, Underwood MD, Tin A, Ellis SP, Mann JJ, Arango V. Elevated expression of tryptophan hydroxylase-2mRNAat the neuronal level in the dorsal and median raphe nuclei of depressed suicides. Mol Psychiatry. 2008;13(5):507-513.
77. BoldriniM, Underwood MD, Mann JJ, Arango V. More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res. 2005;1041(1):19-28.
78. Underwood MD, Khaibulina AA, Ellis SP, et al. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry. 1999;46(4):473-483.
79. Miller JM, Hesselgrave N, Ogden RT, et al. Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry. 2013;74 (4):287-295.